Table 2.
Top 15 differentially enriched transcription factors by PCN, LPS and combined PCN/LPS treatments compared those in the control.
| PCN vs Control | LPS vs Control | PCN/LPS vs Control | PCN/LPS vs PCN/Sal | PCN/LPS vs CO/LPS | |||||
|---|---|---|---|---|---|---|---|---|---|
| Up | Down | Up | Down | Up | Down | Up | Down | Up | Down |
| MEF2 | SP1 | ELK1 | FOXO4 | ELK1 | FOXO4 | ELK1 | FOXO4 | SP1 | |
| PPARG | ELK1 | GABP_B | SP1 | NRF2 | FREAC2 | GABP_B | SP1 | MAZ | |
| NFE2 | FOXO4 | NRF2 | FREAC2 | GABP_B | SP1 | NRF2 | FREAC2 | E12 | |
| MAZ | CETS1P54 | E12 | CETS1P54 | NFAT | ETS2_B | MAZ | LEF1 | ||
| ETS2_B | TEL2 | NFAT | TEL2 | MAZ | STAT5B | LEF1 | NFY | ||
| LEF1 | NFKB | MYC | NFKAPPAB65 | LEF1 | HNF4 | AP4 | FOXO4 | ||
| E12 | COUP | MAZ | NFE2 | E12 | CETS1P54 | NFAT | NFAT | ||
| GABP_B | AP1 | AP4 | CREL | AP4 | NERF | MEF2 | ELK1 | ||
| NFAT | PEA3 | LEF1 | IRF | MYOD | TEL2 | E12 | MYOD | ||
| FREAC2 | CREL | HNF3 | MAX | ERR1 | IRF | MYOD | LEF1 | ||
| AP4 | ATF | ERR1 | BACH1 | LEF1 | STAT5A | MYC | MEIS1 | ||
| HNF3 | CREB | HNF1 | USF | MYC | NFKB | ERR1 | AP4 | ||
| PU1 | BACH1 | CHX10 | ICSBP | CHX10 | PU1 | CHX10 | FREAC2 | ||
| PAX4 | MYCMAX | MYOD | AP1 | HNF3 | ICSBP | NFY | PU1 | ||
| MYC | ATF6 | NKX25 | NERF | MEF2 | SP1 | MEIS1 | E4F1 | ||